Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cardiol Therapeutics Inc T.CRDL

Alternate Symbol(s):  CRDL | T.CRDL.W.A

Healthcare
Cardiol Therapeutics Inc. (Cardiol) is a Canada-based clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). The Company's lead product, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is in a Phase II/III study in hospitalized patients testing positive for COVID-19 with a prior history of, or risk factors for, cardiovascular disease. Cardiol has also received clearance from the Food and Drug Administration (FDA) for its investigational new drug (IND) application for a Phase II international trial that investigates the anti-inflammatory and anti- fibrotic properties of CardiolRx in patients with acute myocarditis, which is a common cause of sudden cardiac death in people under 35 years of age. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure.


TSX:CRDL - Post by User

Cardiol Therapeutics Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(8)
•••
Post by Jordan1159on Aug 25, 2020 8:16am
117 Views
Post# 31449062

COVID ON THE RISE. CARDIOL TO THE RESCUE?

COVID ON THE RISE. CARDIOL TO THE RESCUE?

I woke up this morning and watch the news and it appears that Canada is commencing at second wave of COVID-19.

Sunnybrook hospital in Toronto just had an outbreak.

I hate to see this second wave coming so don't get me wrong but this could put our company here into a pretty cool spotlight if they start to investigate how weed, specifically CBD, can help Covid patients to recover and get better. 

It's worth throwing a couple bucks at the stock. I'm gonna try and pick up a few more today as I think we're in for a pretty decent poppy pop over the next few months. Some of my other dog stocks are down but my hope is in this one.

Does anybody agree with me? 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities